Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05751993 · ClinicalTrials.gov registry record · NA

Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions

A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
19
Enrollment target

NCT05751993: Completed NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT05751993 is a NA study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05751993, a NA study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
19 participants
Enrollment target

Study Summary

The purpose of this pilot study is to conduct a 12-week pilot feasibility study testing usability of a reinforcement learning model (AdaptRL) in a weight loss intervention (ADAPT study). Building upon a previous just-in-time adaptive intervention (JITAI), a reinforcement learning model will generate decision rules unique to each individual that are intended to improve the tailoring of brief intervention messages (e.g., what behavior to message about, what behavior change techniques to include), improve achievement of daily behavioral goals, and improve weight loss in a sample of 20 adults.

Primary Outcome

Feasibility as the success of using the AdaptRL model will be defined as the mean number of messages delivered per participant per day.

Interventions

  • BEHAVIORAL ADAPT

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2025-04-12
Est. Completion 2025-08-18
Phase NA

What the finished NCT05751993 record still lists

NCT05751993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which ADAPT is the first listed.

NCT05751993 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05751993 about?

NCT05751993 is a clinical study titled "Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions". The purpose of this pilot study is to conduct a 12-week pilot feasibility study testing usability of a reinforcement learning model (AdaptRL) in a weight loss intervention (ADAPT study). Building upon a previous just-in-time adaptive intervention (JITAI), a reinforcement learning model will generate...

What is the current status of trial NCT05751993?

This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2025-04-12. Estimated completion is 2025-08-18.

What interventions are being tested in trial NCT05751993?

The interventions under investigation include: ADAPT (BEHAVIORAL).

Who is sponsoring clinical trial NCT05751993?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05751993's enrollment target sits among peer trials

19 1861st of 2000 higher than 138 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05751993, the US trial registry maintained by the National Library of Medicine. NCT05751993 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.